Nature Communications (Dec 2021)
Epithelial phenotype restoring drugs suppress macular degeneration phenotypes in an iPSC model
- Ruchi Sharma,
- Aman George,
- Malika Nimmagadda,
- Davide Ortolan,
- Barbosa-Sabanero Karla,
- Zoya Qureshy,
- Devika Bose,
- Roba Dejene,
- Genqing Liang,
- Qin Wan,
- Justin Chang,
- Balendu Shekhar Jha,
- Omar Memon,
- Kiyoharu Joshua Miyagishima,
- Aaron Rising,
- Madhu Lal,
- Eric Hanson,
- Rebecca King,
- Mercedes Maria Campos,
- Marc Ferrer,
- Juan Amaral,
- David McGaughey,
- Kapil Bharti
Affiliations
- Ruchi Sharma
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Aman George
- Pediatric, Developmental, & Genetic Ophthalmology Section, National Eye Institute, National Institutes of Health
- Malika Nimmagadda
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Davide Ortolan
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Barbosa-Sabanero Karla
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Zoya Qureshy
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Devika Bose
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Roba Dejene
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Genqing Liang
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Qin Wan
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Justin Chang
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Balendu Shekhar Jha
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Omar Memon
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Kiyoharu Joshua Miyagishima
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Aaron Rising
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- Madhu Lal
- Research Governance Council, FDA
- Eric Hanson
- Intramural Research Program, NIAMS, National Institutes of Health
- Rebecca King
- Division of Preclinical Innovation, NCATS, National Institutes of Health
- Mercedes Maria Campos
- Histology Core, National Eye Institute, National Institutes of Health
- Marc Ferrer
- Division of Preclinical Innovation, NCATS, National Institutes of Health
- Juan Amaral
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- David McGaughey
- Ophthalmic Genetics and Visual Functions Branch, National Eye Institute, National Institutes of Health
- Kapil Bharti
- Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health
- DOI
- https://doi.org/10.1038/s41467-021-27488-x
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 18
Abstract
Age-related macular degeneration is characterized by lipid-rich drusen deposits underneath the retinal pigment epithelium (RPE). Here the authors report an in vitro iPSC-RPE model for AMD that recapitulates drusen and RPE atrophy, and identify two drugs that reduce drusen deposits and restore RPE epithelial phenotype.
